<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999878</url>
  </required_header>
  <id_info>
    <org_study_id>hnslblzlzx20210601</org_study_id>
    <nct_id>NCT04999878</nct_id>
  </id_info>
  <brief_title>A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.</brief_title>
  <acronym>RUE-DDGP</acronym>
  <official_title>A Prospective Clinical Study of Ruxolitinib Phosphate Tablets and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhengzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the efficacy and safety of Ruxolitinib and Etoposide combined with DDGP regimen (&#xD;
      cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in the first-line induction&#xD;
      therapy of T cell lymphoma and NK/T cell lymphoma-associated hemophagocytic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, one-arm, prospective clinical collaborative study. This study is aimed to&#xD;
      observe the efficacy and safety of the new combined therapy of Ruxolitinib and Etoposide&#xD;
      combined with DDGP regimen ( cis-Platinum, Dexamethasone, Gemcitabine and Pegaspargase) in&#xD;
      the first-line induction therapy patients with primary central nervous system lymphoma. A&#xD;
      total of 30 patients plan to participate in the study. The primary endpoint is objective&#xD;
      remission rate (ORR) of hemophagocytic syndrome, and the secondary endpoints include&#xD;
      progression-free survival (PFS) , objective remission rate (ORR) of lymphoma, overall&#xD;
      survival (OS), and adverse events(ADR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR of hemophagocytic syndrome</measure>
    <time_frame>28 days</time_frame>
    <description>Objective remission rate of hemophagocytic syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR of lymphoma</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective remission rate of lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADR</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Adverse Reaction Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemophagocytic Syndrome</condition>
  <condition>T/NK-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:&#xD;
Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.&#xD;
Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum</intervention_name>
    <description>All enrolled patients will receive a regimen containing Ruxilitinib, Etoposide, Dexamethasone, Gemcitabine, Pasparase and Platinum for 28 days. The specific medication is as follows:&#xD;
Ruxilitinib 10 mg, bid, d1-28, P.O. Etoposide 100mg per week, two weeks, ivgtt Dexamethasone, 15mg/(m²·d)，d1-12，10 mg/ (m²·d) ，d13-14，5 mg/ (m²·d) ，d15-21，2.5mg/(m²·d)，d22-28，ivgtt or P.O.&#xD;
Gemcitabine, 0.5 g/m², d8, ivgtt Pegaspargase, 2500IU/m², d9, im Platinum, 20mg/m² d10 d11, ivgtt After the treatment, patients will be given disease specific chemotherapy regimen to treat lymphoma according to patient's different lymphoma subtype.</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathologically proven T-cell lymphoma or NK/ T-cell lymphoma;&#xD;
&#xD;
          2. Comply with HLH-2004 diagnostic criteria;Hemophagocytic syndrome can be diagnosed when&#xD;
             either of the following two criteria is met:&#xD;
&#xD;
             A. Molecular diagnosis is consistent with hemophagocytic syndrome. Pathological&#xD;
             mutations were found in known pathogenic genes related to hemophagocytic syndrome,&#xD;
             such as PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST, SH2D1A, BIRC4, ITK, AP3B1, MAGT1,&#xD;
             CD27, etc.&#xD;
&#xD;
             B. Meet 5 of the following 8 indicators I. Fever: The body temperature was &gt; 38.5℃,&#xD;
             lasting &gt; for 7 days. II. Splenomegaly . III. Hemocytopenia (involving two or three&#xD;
             lines of peripheral blood) : hemoglobin &lt; 90g/L, platelet &lt; 100×10^9/L, neutrophils &lt;&#xD;
             1.0×10^9/L and not caused by reduced hematopoietic function of bone marrow.&#xD;
&#xD;
             IV. Hypertriglyceridemia and/or hypofibrinogenemia: triglyceride &gt; 3mmol/L or 3&#xD;
             standard deviations higher than the same age, fibrinogen &lt; 1.5g/L or 3 standard&#xD;
             deviations lower than the same age.&#xD;
&#xD;
             V. Hemophagocytes are found in bone marrow, spleen, liver, or lymph nodes. VI.NK cell&#xD;
             activity decreased or absent. VII. Elevated serum ferritin: ferritin ≥500μg/L. VIII.&#xD;
             Elevated sCD25 (soluble interleukin-2 receptor).&#xD;
&#xD;
          3. Ages 14-75 years.&#xD;
&#xD;
          4. Expected survival of more than 1 week.&#xD;
&#xD;
          5. Patients with left ventricular ejection fraction &gt; 50%, no major bleeding of active&#xD;
             internal organs (digestive tract, lung, brain, etc.), and oxygenation index &gt; 250.&#xD;
&#xD;
          6. Patients have good compliance with the planned treatment and follow-up, can understand&#xD;
             the research process of this study and sign the written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Three or more drugs including ruxolitinb, etoposide, pemasparase, gemcitabine or&#xD;
             cisplatin were used simultaneously in the previous 28 days.&#xD;
&#xD;
          2. Pregnant or lactating women and patients of reproductive age who refuse to take&#xD;
             appropriate contraceptive measures during the course of this study. If the patient was&#xD;
             male, they refused to use adequate contraception or sperm donation during the study&#xD;
             period and for 3 months after the last study of lymphoma-related chemotherapy drugs.&#xD;
&#xD;
          3. Allergic to any medication in the program.&#xD;
&#xD;
          4. Grade III or IV heart disease based on the New York Heart Association (NYHA) score.&#xD;
&#xD;
          5. Major active bleeding of internal organs (including gastrointestinal bleeding,&#xD;
             alveolar bleeding, intracranial bleeding, etc.).&#xD;
&#xD;
          6. Acute pancreatitis.&#xD;
&#xD;
          7. People infected with HIV (HIV antibody positive).&#xD;
&#xD;
          8. HBV DNA copy number is &gt;10^4/ml in patients with acute or chronic active hepatitis B,&#xD;
             and HBV DNA copy number is &gt;10^4/ml in patients with acute or chronic active hepatitis&#xD;
             C (HCV antibody positive, HCV RNA negative acceptable).&#xD;
&#xD;
          9. Participate in other clinical investigators.&#xD;
&#xD;
         10. The investigators identified patients who were not eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Chang, Pro.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Zhengzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mingzhi Zhang, Pro.Dr.</last_name>
    <phone>13838565629</phone>
    <email>Mingzhi_zhang@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Department of The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, Doctor</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Zhengzhou University</investigator_affiliation>
    <investigator_full_name>Mingzhi Zhang</investigator_full_name>
    <investigator_title>the director of oncology department of the first affiliated hospital of Zhengzhou University</investigator_title>
  </responsible_party>
  <keyword>ruxolitinib</keyword>
  <keyword>Lymphoma-associated Hemophagocytic Syndrome</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Pegaspargase</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>cis-platinum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

